The Quantellect read.As of Nov 19, 2026, 5 active firms cover Corvus Pharmaceuticals Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $27.00 to $42.00, a moderate spread. The average target of $34.00 sits 233% above the current $10.21. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.27 next quarter toward $-1.10 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$34.00
+233.0% upside
Average target across 5 active firms as of Nov 19, 2026 vs $10.21 current
Highest Target$42.00
Average Target$34.00
Lowest Target$27.00
Detailed analyst forecasts for CRVS
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate CRVS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CRVS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.27
Range $-0.29 – $-0.25 · 3 analysts · +80% YoY
Next period, 3 analysts expect Corvus Pharmaceuticals Inc to earn $-0.27 a share (range $-0.29 – $-0.25), versus $-0.15 a year earlier. Full-year consensus is $-0.80, growing to $-1.10 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $1.6M next year.
Top analysts covering Corvus Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRVS.
#1
Paul Choi
Goldman Sachs · Rank #110
Buy
$40.00+291.8% to target
Overall win rate
52%
+ Follow
#2
Roger Song
Jefferies · Rank #122
Buy
$42.00+311.4% to target
Overall win rate
43%
+ Follow
#3
Graig Suvannavejh
Mizuho · Rank #239
Buy
$11.00+7.7% to target
Overall win rate
40%
+ Follow
#4
Jeff Jones
Oppenheimer · Rank #320
Buy
$33.00+223.2% to target
Overall win rate
32%
+ Follow
#5
Sean Lee
HC Wainwright & Co. · Rank #344
Buy
$27.00+164.4% to target
Overall win rate
40%
+ Follow
CRVS stock forecast FAQ
What is CRVS's average 12-month price target?+
The 5 active firms with a live target average $34.00 for Corvus Pharmaceuticals Inc over the next 12 months, ranging from a $42.00 high to a $27.00 low, as of Nov 19, 2026.
Is CRVS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CRVS?+
The Street-high target is $42.00 (Jefferies), and the Street-low is $27.00 (HC Wainwright & Co.). The average of all 5 active-firm targets is $34.00.
How many active Wall Street firms cover CRVS?+
5 active firms have a recognized rating on Corvus Pharmaceuticals Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CRVS?+
Among analysts who currently cover CRVS, Paul Choi of Goldman Sachs has the strongest overall Quantellect track record (Rank #110). Their current call is Buy with a $40.00 target.
What is Corvus Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.27 per share (range $-0.29 – $-0.25) across 3 analysts. Full-year EPS is projected at $-0.80, rising to $-1.10 the following year.
How much revenue is Corvus Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $1.6M next year.
Have analysts been upgrading or downgrading CRVS lately?+
As of Nov 19, 2026, 5 of 5 active firms rate CRVS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRVS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.